[go: up one dir, main page]

WO2013016742A1 - Composition utilisable dans le cadre d'un traitement contre l'obésité - Google Patents

Composition utilisable dans le cadre d'un traitement contre l'obésité Download PDF

Info

Publication number
WO2013016742A1
WO2013016742A1 PCT/ZA2011/000054 ZA2011000054W WO2013016742A1 WO 2013016742 A1 WO2013016742 A1 WO 2013016742A1 ZA 2011000054 W ZA2011000054 W ZA 2011000054W WO 2013016742 A1 WO2013016742 A1 WO 2013016742A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
fat
composition according
energy
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ZA2011/000054
Other languages
English (en)
Inventor
Conrad Anton SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/ZA2011/000054 priority Critical patent/WO2013016742A1/fr
Publication of WO2013016742A1 publication Critical patent/WO2013016742A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to the unique combination of three novel dietary supplements for use in a weight loss program.
  • this invention relates to a usage in combination of three novel nutritional agents simultaneously, with each agent targeting a different obesity-promoting category.
  • each of the three nutritional agents displays a unique weight-loss benefit within its own distinctive category and can effectively be used to treat or prevent obesity as a single or standalone treatment strategy.
  • CATEGORY A BEHAVIOUR [0009] Most people gain weight because they eat too much. This could merely be because of bad habits, but often over-eating stems from emotional and medical conditions that make appetite control very difficult.
  • the inventor has demonstrated that large numbers of obese individuals had undiagnosed psychological disorders such as the Binge Eating Disorder (Obsessive Compulsive Disorder), Attention Deficit Disorder (ADHD/ADD) and other mood disorders, (such as depression) and anxiety disorders (such as Generalised Anxiety Disorder), conditions that all lower levels of compliance and motivation. Giving these individuals a meal-plan of whatever kind without helping them address their underlying perceptive emotional disorder sets them up for failure right from the start and is therefore a futile exercise.
  • Binge Eating Disorder Obsessive Compulsive Disorder
  • ADHD/ADD Attention Deficit Disorder
  • other mood disorders such as depression
  • anxiety disorders such as Generalised Anxiety Disorder
  • Insulin has several different effects that lead to fat accumulation in adipose tissue. Firstly, insulin promotes fat synthesis. When the quantity of glucose that enters the liver cells is more than what can be stored as glycogen, insulin promotes the conversion of excess glucose into fatty acids. These fatty acids are subsequently packaged as triglycerides in very low density lipoproteins and transported to the adipose tissue where they are deposited as fat. However, insulin also increases the utilisation of glucose by most of the body's tissues, which automatically decreases the utilisation of fat, thus functioning as a "fat sparer". [0014] Secondly, insulin plays a role in fat storage.
  • insulin By inhibiting the action of hormone-sensitive lipase, an enzyme that causes hydrolysis of the triglycerides already stored in the fat cells, insulin inhibits the release of fatty acids into the circulating blood stream, thereby promoting obesity. Insulin also promotes glucose transport through the cell membrane into the fat cells in the same way that it promotes glucose transport into the muscle cells. Although some of this glucose is then utilized to synthesize small amounts of fatty acids, the glucose also forms large quantities of glycerophosphate which supplies the glycerol backbone that combines with fatty acids to form triglycerides molecules which are a dominant storage form of fat in adipose cells. Therefore, when insulin is not available, storage of a large amount of fatty acids transported from the liver via lipoproteins is almost totally blocked.
  • Fat cells have historically been accredited with two main functions, namely that of storing energy and preserving body temperature via insulation.
  • fat cells once filled with fat, also assume a hormonal function by manufacturing and releasing various chemical substances called inflammatory cytokines, able to mimic or interfere with normal hormonal functions.
  • inflammatory cytokines able to mimic or interfere with normal hormonal functions.
  • some of these inflammatory cytokines disrupt insulin's role on cellular level (at the insulin receptor that regulates the glucose portal across the cell membrane) and render insulin less effective.
  • the medical term for this condition is 'insulin resistance'. To get the same task done as before, the body compensates by producing even more insulin, and insulin levels rise above the norm.
  • the invention in this category is based on the proposition that aspects of fat breakdown and use for providing energy are enhanced in the absence of insulin. This can occur normally between meals when secretion of insulin is minimal but the effect becomes extreme in diabetes mellitus when secretion of insulin, is almost absent. When this happens, the aforementioned effects of insulin causing the production and storage of fat, are reversed.
  • a dominant effect is that the enzyme hormone-sensitive lipase in the fat cells becomes strongly activated. This causes hydrolysis of stored triglycerides, releasing large quantities of fatty acids and glycerol from the adipose tissue into the circulating blood. The net effect is significant weight- loss.
  • a goal in this respect is a strategy in which the insulin level is lowered to a value which is still healthy but which does not promote fat deposition and fat storage, thereby counteracting insulin's obesity-promoting effects.
  • the invention is inter alia based on the use of a combination of naturally derived compounds and plant extracts that display complementary and synergistic pharmaceutical effects, all of which have been proven to be useful for the treatment or alleviation of insulin resistance.
  • the mode of action is via an unique mechanism, which optimises catabolic metabolism by lowering insulin levels and increasing the usage of fat for energy purposes, thereby assisting with weight loss.
  • Fat contains more than twice the amount of energy as the same quality of carbohydrate and protein.
  • the human intestine is able to absorb 95% of all dietary fat, and it is therefore not surprising that a high fat diet is readily converted into fatty tissue, especially in individuals with a slow metabolic rate.
  • each triglyceride consist of three smaller building blocks, called fatty acids, bonded together by a larger carrier molecule called glycerol. Triglyceride molecules are far too large to be absorbed through the intestinal wall, and therefore need to be broken down into smaller particles. This happens during the process of digestion, when fat-digesting enzymes split the bonds between fatty acids and set them free. Once released, each individual fatty acid freely passes through the wall of the small intestine and enters the body.
  • Fats are medically called 'lipids'. Fat digestion is therefore called 'lipolysis' and the fat-digesting enzymes responsible for this process are the 'lipases". There are several different lipases, released throughout the gastro-intestinal tract. Lipolysis takes place via the combined action of different lipases. The rate at which lipolysis takes place and the consequent supply of free fatty acids to the body can be affected by various factors. These include certain biochemical agents, many of which are naturally occurring or derived from nature.
  • carbohydrates are too large to be absorbed into the system without the splicing action of digestive enzymes. All carbohydrates are constructed from the elements carbon, hydrogen and oxygen, arranged in a three dimensional ring-like structure. A single ring is called a monosaccharide, two rings are a disaccharide, whilst those with more than two rings are the polysaccharides. For obvious reasons, monosaccharides are the smallest carbohydrate molecules and can be absorbed directly into the body without the need for digestion. Monosaccharides include glucose, the dominant energy molecule of the body, as well as fructose or 'fruit sugar', naturally found in fruit and fruit juice.
  • the disaccharides include table sugar and milk sugar, whilst the polysaccharides form the various starches. These two groups are the most important source of calories consumed in the average Western diet. Being too large to be absorbed, both disaccharides and polysaccharides require reduction through digestion into smaller molecules like glucose and fructose which can be absorbed and utilised as energy.
  • Nutrients are essential to health and the dominant reason all living creatures must eat a variety of nutritious food. Nutrients enter the body and are absorbed via the intestines. Antinutrients, however, are agents that block or interfere with the absorption of nutrients. Antinutrients are either natural or synthetic compounds and are found at some level in almost all foods for a variety of reasons, including food items that we consume on a daily basis. A common example is phytic acid, found abundantly in sodas and junk food. Phytic acid has the ability to form insoluble complexes with calcium, zinc, iron and copper, thereby reducing their absorption in the intestines and potentially causing a shortage.
  • each of the three nutritional agents displays a unique weight-loss benefit within its own distinctive category and can effectively be used to treat or prevent obesity as a single or standalone treatment strategy.
  • the invention is based, however, on the premise that the use of three anti- obesity products, each targeting different obesity promoting mechanisms, will have a synergistic weight loss effect in subjects.
  • a premise is that the use of a mood enhancer, included in a weight loss program, may be beneficial. It is believed that the effects of a mood enhancer, such as increased endurance and diminished fatigue as well as a heightened sense of emotional and mental wellbeing, would help a subject to be more inclined to begin with, and adhere to, an exercise and diet program.
  • a mood enhancer identified as being suitable for use in a weight-loss program, consists of a composition of a plant extract, neutraceutical food extract and two essential minerals, namely inositol, rhodiola rosea, magnesium and zinc, respectively.
  • Rhodiola rosea is a plant that grows in cold regions around the world. These regions include the Arctic, the mountainous areas of central Asia, the Alps, Scandinavia and Iceland. Traditionally, Rhodiola rosea was used by Siberians and Scandinavians to improve vitality in harsh conditions presented by bitter cold climates and high altitude areas. To improve physical and mental endurance while persevering under stressful conditions, Rhodiola was routinely given to Soviet cosmonauts, KGB secret agents and special force soldiers. Various studies have assessed Rhodiola extract's effect on the neurological function of humans and animals In particular, studies on human subjects have shown that it improves mood by displaying the rare quality of alleviating both the symptoms of depression and anxiety.
  • Rhodiola's mode of action appears to be mediated by its influence on the levels of the two most important "happiness” neurotransmitters, namely serotonin and dopamine.
  • Rhodiola rosea extract exerts an anti-fatigue effect that improves general mental performance and increases the ability to concentrate in healthy subjects.
  • One such double-blind, cross-over study examined this effect in healthy physicians during night duty. During this trial, a statistically significant improvement in perceptive and cognitive cerebral functions was measured in all the doctors that participated in the trail.
  • Inositol occurs naturally as phytic acid in the fibre component of certain plant foods, and as myo-inositol in meat. Myo-inositol is found to bio-accumulate most abundantly in the central nervous system, where it plays an important role as the structural basis for numerous signalling and secondary messenger molecules. These play a crucial role in a number of biological processes, including nerve guidance, the modulation of serotonin's activity, gene expression and the assembly of the cytoskeleton of neurons.
  • inositol supplementation shows promising results for people suffering from neuro-psychological conditions such as generalised anxiety disorder, panic disorder, obsessive-compulsive disorder, bulimia, agoraphobia and depression.
  • inositol proved superior to fluvoxamine, a popular antidepressant belonging to the class of SSRI drugs, (serotonin selective reuptake inhibitors), for decreasing the number of panic attacks.
  • TRD treatment-resistant depression
  • Magnesium-deficiency is known to lead to the dysfunctional opening of specialised calcium channels (N-methyl-d-aspartate /NMDA coupled), thereby causing neuronal injury and subsequent neurological dysfunction. It is postulated that this pathological development may present in humans with the symptom of depression. Evidence from several studies strongly links magnesium with the intracellular and interneuronal processes associated with certain mood disorders, especially depression.
  • magnesium supplementation was comparable to the anti-depressant drug imipramine.
  • Zinc stimulates the activity of about 100 different enzymatic reactions in the body and, like magnesium, is an important modulator of glutaminergic transmission in the brain.
  • a growing body of evidence implicates a derangement of zinc homeostasis in the psychopathology as well as treatment of mood disorders.
  • Zinc's antidepressant-like activity has been examined in a variety of tests and models in laboratory animals as well as human studies.
  • zinc supplementation significantly reduced depression scores and facilitated the treatment outcome in antidepressant treatment resistant patients.
  • a premise is that the use of an insulin sparing agent, included in a weight loss program, may be beneficial. It is believed that the effect of lowering insulin levels, via a unique triple action mechanism, is beneficial to weight loss for the reasons mentioned hereinbefore.
  • the dietary insulin sparing component of the invention is a combination agent indicated for the treatment of insulin resistance, obesity and metabolic syndrome. It contains three biological actives, namely berberine , banaba leaf and inositol.
  • Berberine is a quaternary ammonium salt from the group of isoquinoline alkaloids found in plants such as Berberis, Hydrastis canadensis and Coptis chinenses. Berberine has demonstrated the property of being able to up-regulate activity on both low-density-lipoprotein receptors (LDLR), as well as insulin receptors (InsR). To explain how this mechanism works, one has to touch on the topic of two common biological processes that happen throughout the body and which, to a large degree, control how the body communicates with cells. These processes are called 'downregulation' and 'upregulation'.
  • LDLR low-density-lipoprotein receptors
  • InsR insulin receptors
  • Each cell contains a certain amount of receptors on its surface membrane.
  • the number of receptors can be increased (“upregulate”) or decreased (“downregulated”). If a cell has fewer receptors on its surface membrane, it is less sensitive to a chemical messenger that is attempting to communicate with the cell. Examples of chemical messengers are hormones and neurotransmitters. Pharmaceutical drugs, however, or toxins, for that matter, may also occupy these receptors and act as chemical messengers.
  • An example of downregulation can be illustrated by the insulin receptor sites on the cells of a person with type 2 diabetes. If the number of receptors on the surface membrane decreases, the sensitivity of the membrane to insulin will also decrease. The body will compensate for this by releasing more insulin to complete the same task.
  • Insulin levels drop by up-regulating activity on insulin receptors (InsR).
  • InsR insulin receptors
  • Studies on berberine demonstrate berberine's ability to stimulate glucose transport across the cell membrane to lower elevated blood glucose levels, to prevent or alleviate insulin resistance, to increase insulin receptor expression and to inhibit adipogenesis in human white preadipocytes.
  • Banaba (Lagerstroemia speciosa) is a medicinal plant that grows naturally in India, Southeast Asia and the Philippines. Tea brewed from the leaves is traditionally used to treat diabetes in Eastern medicine and has been in use for over a century. The hypoglycaemic effect of banaba leaf extract has been shown to be similar to that of insulin. The blood sugar regulating properties of banaba and its ability to increase insulin sensitivity have scientifically been demonstrated in cell culture, animal and human studies. Tighter blood sugar control and a reduction in insulin levels have also demonstrated weight-loss in trials, even in the absence of dietary alterations.
  • inositol occurs naturally as phytic acid in the fibre component of certain plant foods, and as myo-inositol in meat. It has an important role as a structural basis for numerous signalling and secondary messenger molecules that play a crucial role in a number of biological processes, including insulin signal transduction.
  • PCOS polycystic ovary syndrome
  • inositol increases the action of insulin by improving insulin sensitivity.
  • study subjects benefited by showing improved ovulatory function, decreased blood pressure and plasma triglyceride concentrations.
  • a premise is that the use of a peripheral energy blocker, included in a weight loss program, may be beneficial. It is believed that the effects will assist obese individuals by preventing the digestion of excess fat and refined carbohydrates in their diet, thereby allowing it to pass through their systems without getting absorbed.
  • apple extracts inhibited lipase activity by more than 70%. Apples contain several different phenolic substances, which include chlorogenic acid, catechin, phorodzin, rutin and some procyanidins. Other studies have also demonstrated that apple polyphenols display highly effective lipase blocking activity.
  • Salacia reticulata is a climber found in Sri Lanka and India. Its roots and stems have been used to treat diabetes for centuries. In Japan, Salacia is consumed as a food supplement for the purposes of suppressing high blood sugar levels. Pharmacological studies have demonstrated that various multi-target actions contribute to Salicia root-extract's improvement of type 2 diabetes, high blood sugar and cholesterol levels, conditions commonly associated with obesity. scientistss have found that Salacia's effects are mainly due to the presence of highly potent glucosidase inhibitors.
  • the main compounds responsible for a-glucosidase inhibition are salicinol, kotalanol and ponkoranol.
  • kotalanol demonstrated more potent inhibitory activity against sucrase, the enzyme that digests sucrose (table sugar), than the diabetic drug acarbose.
  • sucrase the enzyme that digests sucrose (table sugar)
  • Various studies have shown that the oral administration of a Salacia reticulata extract suppressed body weight gain without affecting food intake.
  • a peripheral energy blocker containing all the above agents in a proprietary blend, assists obese individuals by preventing the digestion of excess fat and refined carbohydrates. But, besides blocking calorie intake, the peripheral energy blocker has also been designed to assist with appetite control.
  • the stomach also plays a role in the regulation of appetite. If one has not had food for a while, the stomach undergoes a series of rhythmic contractions, which present as gnawing, cramp-like sensations in the pit of the stomach. These are commonly referred to as 'hunger pangs'.
  • signals from the stomach suppress the feeding centre in the brain, thereby reducing the desire to eat. This mechanism is controlled by nerves which link the stomach with the feeding centre, as well as various chemical messengers, the dominant player being the hormones cholecystokinen and grehlin, released by the intestines when food enters the stomach.
  • Salacia reticulata 50 10 - 450 [0071] A daily dosage constitutes between 1-2 tablet of each product between 1-3 times per day.
  • Group I and Group II each consisted of 5 subjects.
  • Group I was administered a placebo for the first 15 weeks and then switched to a supplement of the three products for the remainder of the 30 week period.
  • Group II was administered a supplement of the three products for the duration of the 30 week period.
  • Table 4 indicates that the average total weight loss and average weekly weight loss recorded for Group II is more than double that of Group I.
  • the cholesterol and glucose content of the blood substantially decreased for the Group II, whereas the cholesterol content of Group I had increased and the glucose decrease was significantly less in this group.
  • the average BMI and waist circumference reduction were also significantly more in Group II.
  • Table 5 indicates that Group I results for the last 15 weeks of the trial showed a significant increase in average weight loss and BMI and waist circumference reduction. It also indicates a substantial decrease in the blood cholesterol content and blood glucose content in the subjects in the final 15 weeks compared to the first 15 weeks.
  • Table 6 compares the results of the final 15 weeks of both groups. The results show similar weight loss and similar BMI and waist circumference reductions. The reductions in blood cholesterol and blood glucose content are significantly more in Group I compared to Group II. [0083] The results in Table 5 and 6 are an indication that the supplements administered to the subjects are a likely cause of the weight reduction and blood cholesterol and blood glucose content reduction observed.
  • Table 7 indicates a smaller decrease in the blood cholesterol and glucose content in the final 15 weeks compared to the first 15 weeks.
  • the average weight loss and BMI reduction and waist circumference reduction remained more or less unchanged. This indicates that weight loss, blood cholesterol and glucose reduction, as well as BMI and waist measurements, reached respective plateaux.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition permettant de traiter l'obésité et contenant un renforçateur d'humeur, un agent d'épargne de l'insuline et un agent capable de priver les tissus périphériques d'énergie.
PCT/ZA2011/000054 2011-07-22 2011-07-22 Composition utilisable dans le cadre d'un traitement contre l'obésité Ceased WO2013016742A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000054 WO2013016742A1 (fr) 2011-07-22 2011-07-22 Composition utilisable dans le cadre d'un traitement contre l'obésité

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000054 WO2013016742A1 (fr) 2011-07-22 2011-07-22 Composition utilisable dans le cadre d'un traitement contre l'obésité

Publications (1)

Publication Number Publication Date
WO2013016742A1 true WO2013016742A1 (fr) 2013-01-31

Family

ID=44543899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2011/000054 Ceased WO2013016742A1 (fr) 2011-07-22 2011-07-22 Composition utilisable dans le cadre d'un traitement contre l'obésité

Country Status (1)

Country Link
WO (1) WO2013016742A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
US9849151B2 (en) 2013-11-19 2017-12-26 OmniActive Health Technologies (Canada) Limited Salacia compositions, methods of treatment by their administration, and methods of their preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107779A2 (fr) * 2004-04-30 2005-11-17 New Hc Formulations Ltd. Composition nutritionnelle permettant de perdre du poids, de bruler des calories, d'augmenter la thermogenese, de favoriser le metabolisme energetique et/ou de suprrimer l'appetit
US20060040003A1 (en) * 2004-08-10 2006-02-23 Alvin Needleman Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
WO2010104595A1 (fr) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires
JP2010202634A (ja) * 2008-06-05 2010-09-16 Green Kanpo Seiyaku Kk 生薬含有組成物及びその利用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107779A2 (fr) * 2004-04-30 2005-11-17 New Hc Formulations Ltd. Composition nutritionnelle permettant de perdre du poids, de bruler des calories, d'augmenter la thermogenese, de favoriser le metabolisme energetique et/ou de suprrimer l'appetit
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
US20060040003A1 (en) * 2004-08-10 2006-02-23 Alvin Needleman Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
JP2010202634A (ja) * 2008-06-05 2010-09-16 Green Kanpo Seiyaku Kk 生薬含有組成物及びその利用
WO2010104595A1 (fr) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Méthodes et compositions utilisées pour le traitement de maladies métaboliques et cardiovasculaires

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849151B2 (en) 2013-11-19 2017-12-26 OmniActive Health Technologies (Canada) Limited Salacia compositions, methods of treatment by their administration, and methods of their preparation
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
WO2017187375A1 (fr) * 2016-04-29 2017-11-02 Sochim International S.P.A. Composition pour le traitement du syndrome des ovaires polykystiques
EP3448370B1 (fr) 2016-04-29 2020-10-21 Sochim International SpA Composition pour le traitement du syndrome des ovaires polykystiques

Similar Documents

Publication Publication Date Title
AU2002364213B2 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
KR101341475B1 (ko) 부작용 없이 건강하게 체중감량이 가능한 다이어트 식품 조성물 및 그 제조방법
US20140017337A1 (en) Therapeutic methods
WO2005023021A1 (fr) Denree alimentaire dietetique
Talbott et al. The health professional's guide to dietary supplements
US8420131B2 (en) Composition for obesity treatment
RU2449600C1 (ru) Биологически активная пищевая добавка
Blum et al. Genotrim™, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine–glucose correlation demonstrating reward deficiency syndrome (RDS)
KR101447760B1 (ko) 삼환형 다이터펜 및 이의 유도체의 혼합물을 함유하는 세이지 추출물을 포함하는 식이 및 약학 조성물 및 이의 용도
Emmons The chemistry of joy: A three-step program for overcoming depression through western science and eastern wisdom
WO2013016742A1 (fr) Composition utilisable dans le cadre d'un traitement contre l'obésité
CN102613461B (zh) 迅美减肥营养品及其制备方法
US20230180810A1 (en) Dosage forms and methods of preparation and use thereof
US20070298057A1 (en) Composition and method for modulating addictive behaviors
CN101703249A (zh) 具有调节内分泌、提高免疫力作用的保健品及制备方法
KR20040097813A (ko) 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물
Sagar et al. An survey on obesity stigma and its assessment with update: A review
US8349373B1 (en) Dietary supplement for use in a weight loss program
CN102631503A (zh) 一种抗疲劳中药组合物及其制备方法
Premlata et al. Jitendra Khachariya. Role of Vidangadi Kwatha in Madhumeha (Diabetes Mellitus Type II)
CN106819223A (zh) 一种保健奶茶及其制备方法
WO2013016741A1 (fr) Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement
CN102630945A (zh) 一种养生组合物
RU2722728C1 (ru) Набор для контроля аппетита и нормализации веса тела и способ его применения
Górska et al. Apple Cider Vinegar in the Combat Against Type 2 Diabetes and Obesity–An Overview of Recent Research

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751784

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751784

Country of ref document: EP

Kind code of ref document: A1